# Lillian L. Siu

Source: https://onco.cc/people/lillian-siu/  
OnCo record `lillian-siu` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Runs one of the world's largest phase 1 programmes and led trials that shaped head and neck cancer immunotherapy.

## Summary

Lillian L. Siu is Director of the Phase I Program and holds the BMO Chair in Precision Cancer Genomics at the Princess Margaret Cancer Centre. She is a medical oncologist who runs one of the world's largest phase 1 programmes and led KEYNOTE and other immunotherapy studies that shaped head and neck cancer treatment. Her selected paper reports the CONDOR trial of durvalumab with or without tremelimumab in PD-L1-low or negative recurrent or metastatic head and neck squamous cell carcinoma. She pioneers ctDNA-guided early trials and is AACR president for 2025 to 2026.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Phase I Program; BMO Chair in Precision Cancer Genomics
- Specialisms: Early drug development; Head and neck cancer; Immunotherapy; ctDNA

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Lillian_Siu
- UHN profile: https://www.uhnresearch.ca/researcher/lillian-l-siu
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Siu%20LL%5BAuthor%5D

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)
- institutions: [Princess Margaret Cancer Centre](https://onco.cc/institutions/princess-margaret/)

---
JSON: https://onco.cc/api/v1/entities/lillian-siu.json